Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome Academic Article uri icon

Overview

MeSH Major

  • Myasthenia Gravis
  • Neuromuscular Junction
  • Piperazines
  • Protein Kinase Inhibitors
  • Protein-Tyrosine Kinases
  • Quinazolines

abstract

  • This study provides Class III evidence that tandutinib 500 mg twice daily induces reversible muscle weakness and electrophysiologic changes consistent with neuromuscular junction dysfunction.

publication date

  • January 18, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3034397

Digital Object Identifier (DOI)

  • 10.1212/WNL.0b013e3182074a69

PubMed ID

  • 21242491

Additional Document Info

start page

  • 236

end page

  • 41

volume

  • 76

number

  • 3